Assess the Safety of a Microneedle Patch for Vaccination Against Rotavirus When Given Intradermally for Four (4) Administrations in Rats
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Centers for Disease Control and Prevention (CDC), National Center for Immunizations and Respiratory Diseases (NCIRD), has issued a Notice of Intent to Award a Sole Source Contract to Southern Research Institute (Birmingham, Alabama). This notice is for a study to assess the safety of a rotavirus vaccine microneedle patch and is not a request for competitive quotes. Interested parties must submit capability statements by April 9, 2026, to demonstrate their ability to perform these services.
Scope of Work
The primary objective of this project is to assess the safety of a Live Attenuated Rotavirus Vaccine (LARV) Microneedle (MN) patch. The assessment will involve intradermal administration for four (4) administrations in rats, conducted in accordance with regulatory requirements. The study aims to evaluate the safety profile of this novel vaccination method.
Contract & Timeline
- Type: Notice of Intent to Award Sole Source (Firm Fixed Price)
- Recipient: Southern Research Institute
- Authority: FAR 13.106-1(b)(1)(i) and 10 U.S.C. 2304(c)(1)
- NAICS: 541715 (Research and Development In The Physical, Engineering And Life Sciences (Except Nanotechnology And Biotechnology))
- Period of Performance: May 15, 2026 – May 14, 2028
- Anticipated Award Date: On or before May 15, 2026
- Set-Aside: Not Applicable (Sole Source)
- Capability Statement Due: April 9, 2026, 10:00 AM Eastern Standard Time (EST)
- Published: March 25, 2026
Submission Requirements
Sources interested in responding to this notice are required to submit a capability statement. This statement must include management, technical, and cost information, provided in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the requested services and warranties.
- Format: Maximum 2 pages (8.5 x 11 inch), using a font size no smaller than 10-point.
- Submission Method: Email ONLY as a Microsoft Word or Adobe PDF attachment.
- Email Address for Submissions: TPW8@cdc.gov
- Important Note: Telephone requests will not be honored. Submissions that only ask questions will not be considered. The Government's determination on whether to compete based on responses is solely at its discretion. Information received will be used to determine if a competitive procurement is feasible or if the sole source contract should proceed.
Contact Information
For general inquiries, contact Tim Williams at TLWilliams3@cdc.gov or 770-488-2791.